Non-bullous congenital ichthyosiform erythroderma (NBI) is a rare inherited skin disorder characterized by marked keratinization and inflammation of the skin. It manifests itself as generalized erythema, scaling, thickening, and dryness of the skin, leading to discomfort and indirect consequences in the form of dermatological and systemic complications. These manifestations appear in early childhood and can persist throughout life. NBI is often associated with changes in lipid levels and impaired skin barrier function, which is due to genetic mutations affecting keratinocytes. The disease has a complex and multifactorial pathogenesis, which complicates diagnosis and treatment.
History of the disease and interesting historical facts
Nonbullous congenital ichthyosiform erythroderma has been described in medical literature since the late 19th century. The first reports of similar skin manifestations were made in the works of dermatologists such as Vinogradov and Fisher, who noted the extreme uniqueness of the symptoms and parasitic theories of pathogenesis. Over time, accumulated data on the hereditary nature of the disease, as well as the history of the spread of NCI in various populations, have enriched our understanding of its clinical characteristics. An important stage in the study of the disease was 1988, when it was established that the pathology is associated with mutations in the genes responsible for skin keratinization. Since then, research in the field of molecular genetics has helped to identify specific mutations and learn to distinguish NCI from other forms of ichthyosis, which has significantly improved diagnosis and treatment.
Epidemiology
The epidemiology of NVIE shows different statistical data depending on the populations studied. According to current data, the incidence ranges from 1 in 400,000 to 1 in 600,000 live births. Depending on geographic and ethnic factors, the incidence rate may vary, which may be due to different degrees of genetic predisposition in populations. For example, in some families with a high incidence of the disease, both male and female predominance is observed, which makes epidemiological studies more difficult. Genetic parameters, such as the frequency of mutations in the relevant genes, also affect the incidence and difficulties in diagnosis among different ethnic groups.
Genetic predisposition to this disease
Non-bullous congenital ichthyosiform erythroderma is caused by inherited mutations, mainly in genes encoding proteins involved in the process of keratinization and the formation of the barrier function of the skin. The most common mutations are in genes such as TGM1 (transglutaminase 1 gene), which leads to a disruption of keratin synthesis and pathological changes in the structure of the stratum corneum. In addition, other genes are also involved, such as KRT1 and KRT10, which are responsible for the formation of the stratum corneum. In most cases, the disease is inherited in an autosomal recessive manner, which means that two copies of the mutant gene are required for the clinical picture to manifest - one from each parent. The study of genetic markers of NCI has become the basis for the development of molecular genetic tests, which allows identifying carriers of pathogenic mutations and timely initiation of preventive measures.
Risk factors for the development of this disease
There are various risk factors that contribute to the development of renewable energy sources. These include:
- Hereditary factors: the presence of a similar disease in parents or their close relatives increases the likelihood of its manifestation in offspring.
- Climate conditions: Living in areas with high temperatures and low humidity can aggravate the symptoms of the disease.
- Immunological status: Children with weakened immune systems are more susceptible to infections, which can worsen the skin condition of patients with NVI.
- Contact with chemicals: Certain chemicals may worsen the condition by causing inflammation or irritation of the skin.
- Physical factors: mechanical irritation of the skin, overheating or hypothermia can provoke exacerbations.
Diagnosis of this disease
Diagnosis of NVIE is based on a comprehensive clinical and laboratory examination. The main symptoms include:
- Severe redness of the skin (erythema),
- Peeling and dry skin,
- Symptoms of inflammation,
- Exacerbations of skin disorders, especially in areas subject to friction.
Laboratory tests may include skin biopsy to evaluate morphological changes in the stratum corneum, and molecular genetic tests to detect mutations in specific genes. Radiological examinations are not mandatory in this case, but may be useful to exclude concomitant diseases. Differential diagnosis of NVIE should be carried out with other dermatological diseases, such as common ichthyosis, eczema and other hereditary dermatoses, which requires an experienced approach from a dermatologist.
Treatment
Treatment of NVIE should be comprehensive and individually selected. The main areas of treatment include:
- General treatment methods: maintaining normal skin moisture levels, using moisturizers and emollients, which helps in reducing manifestations and improving barrier function.
- Pharmacological treatment: Corticosteroids are sometimes used to reduce inflammation, as well as antihistamines to reduce itching.
- Surgical treatment: In severe cases, surgery may be considered to correct the affected areas of the skin.
- Other methods: Physical therapy, such as laser therapy, may be used to improve skin condition and reduce itching.
Well-chosen treatment can significantly improve the quality of life of patients with NVI.
List of medications used to treat this disease
The following groups of drugs can be used in the treatment of NVIE:
- Creams and ointments containing corticosteroids (eg, betamethasone),
- Emollients and moisturizers (eg, petroleum jelly, urea-based creams),
- Antihistamines (eg, cetirizine),
- Anti-inflammatory drugs (eg, ibuprofen),
- Antibiotics to treat bacterial infections.
The choice of specific drugs depends on the severity of the disease and the individual characteristics of the patient.
Disease monitoring
Monitoring the condition of patients with NVIE plays an important role in the timely detection of complications and directs to the adjustment of therapy. Control stages include regular dermatological examinations, assessment of the skin condition and the level of comorbid conditions. The prognosis of NVIE depends on the timeliness of diagnosis and the beginning of treatment. Complications may include secondary bacterial infections, as well as psychosocial problems associated with the appearance and chronic condition of the patient. Timely and adequate therapy can significantly improve the prognosis and quality of life.
Age-related features of the disease
NVIE can manifest itself in different age groups, but symptoms most often begin to appear in the neonatal period. In newborns, the severity of skin manifestations can be especially severe and they require immediate intervention. In school-age children and adolescents, the condition may worsen with a change in climate or improper skin care. In older patients, as a rule, less pronounced manifestations are observed, but the risk of complications increases.
Questions and Answers
- What is the cause of NVE disease? NVE is caused by hereditary mutations in genes responsible for skin keratinization and the formation of barrier function; mutations in the TGM1 gene are common.
- Is it possible to completely cure NVE? NVE is considered a chronic condition and a complete cure is not possible, but significant improvement in skin condition and reduction of symptoms can be achieved with proper therapy.
- What are the main treatments for NVE? Treatment includes the use of moisturizers, corticosteroids, antihistamines, and physical therapy.
- Are there any age differences in the manifestation of NVE? Yes, the manifestations of the disease can vary depending on age, with symptoms being most pronounced in newborns.
- What complications can arise with NVIE? Complications may include secondary bacterial infections as well as psychosocial problems associated with the skin condition.
Non-bullous congenital ichthyosiform erythroderma is a complex disease that requires careful approach to diagnosis and treatment. Systemic treatment and regular monitoring of patients' condition will help improve quality of life and reduce the risk of complications.
